Lung Cancer

We all handle things differently, look at things differently and understand differently, meaning that the journey of each patient with cancer is unique. But there are always similarities among the symptoms, risks and treatments.

Over the past few years, lung cancer has changed significantly with improving outcomes, particularly attributable to immunotherapy, but how do we continue that trend?

Because of their age, disease state and comorbid conditions, older patients need supportive care.

As part of its “Speaking Out” video series, CURE® spoke with Katie Brown from LUNGevity about challenges that have arisen from the COVID-19 pandemic — including delays in screening — and resources to help patients through these trying times.

In partnership with CURE®, Bonnie J. Addario and the GO2 Foundation for Lung Cancer will release “The Living Room: A Lung Cancer Community of Courage,” a collection of stories from patients, caregivers and survivors taking a personal approach to cancer care.

The Cancer Support Community's Biomarker Testing Tool can help identify which targeted therapy should be used for treatment in patients with lung cancer.

In recent years, research in treating small cell lung cancer has broadened, bringing emerging therapies like immunotherapy to the forefront.

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

Recent study results demonstrated an possible association between a high BMI and risk of cancer and overall mortality, though patients with obesity and lung cancer, renal cell carcinoma and melanoma were found to have a lower risk of death than patients with the same cancers without obesity.

On Feb. 18, CURE hosted a webinar focused on educating patients on biomarker testing. Here, we highlight key takeaways from our panelists.

Mesothelioma has been categorized as an “older persons” disease, writes a 14-year survivor. Which is why, she writes, her and her family were completely caught off-guard when she was diagnosed at 21.

Take a look back at CURE®’s Educated Patient® Lung Cancer Summit with this roundup of stories that highlight what was discussed at this half-day virtual event.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for March 2021.

The FDA recently approved an expanded indication for Lorbrena as a first-line treatment option for a subset of lung cancer that has spread to the brain. Compared to previously-approved options, experts say Lorbrena is more effective.

Previously, treatments for patients with extensive-disease small cell lung cancer were limited with a poor prognosis. Researchers sought to investigate if Opdivo plus Yervoy or Opdivo alone would improve survival.

Here is a list of some recent trials that launched within the cancer space in March.

The FDA’s fast track designation to poziotinib for use in previously treated patients with non-small cell lung cancer whose disease harbors a certain genetic mutation, may open the doors to an accelerated approval.

In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.

A trial investigating a novel drug plus the chemotherapy docetaxel failed to show a survival benefit in patients with previously treated locally advanced or metastatic non–small cell lung cancer.

As the population ages, the incidence of older adults being diagnosed with lung cancer is increasing, though data on how to specifically treat this population are lacking.